The last 20 years have witnessed a tremendous increase of interest in the role of vascular endothelium in health and disease. The concept of endothelium serving as an inert barrier between blood and the surrounding tissues was first depicted in the middle of the last century. According to that model, molecular exchanges across the vessel wall were simply regulated by the interplay between hydrostatic and osmotic pressures, endothelium serving the sole purpose of providing a physical barrier. Later on, progress in the knowledge of blood clotting and its mechanisms required the addition of a new feature, namely anti-thrombogenicity. It was mainly after the development of methods for culturing endothelial cells [11 that the idea of a passive semi-permeable, anti-coagulating nucleated cellophane gave way to a more complex and dynamic model. We now know that endothelium is a widespread organ of multiple capabilities which is actively involved in a number of heterogeneous processes, including the maintenance of the vessel wall integrity, the blood clotting system, the clearance of circulating lipids, the renin-angiotensin system, the endocrine system, and the immune response.
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Endothelium is characteristically damaged in a number of chronic illnesses, notably autoimmune diseases, atherosclerosis and diabetes. This review is aimed at reviewing the current knowledge on those aspects of endothelial pathophysiology that appear more specifically involved in the pathogenesis of diabetic microangiopathy.
Morphology
Endothelium lines the luminal surface of large vessels with a monolayer of polygonal oblong cells stretching their longer diameter along the direction of blood flow. In small vessels this "cobblestone" pattern desappears, as individual cells may fold their cytoplasm to encircle the entire capillary lumen. In both cases, the cells remain firmly attached to the basement membrane and are flattened, producing a high surface/volume ratio.
The intracellular endowment of organelles includes numerous free ribosomes, a well developed rough endoplasmic reticulum and Golgi apparatus, both suggestive of intensive synthetic and metabolic activities, and more specific features such as vesicles, Weibel-Palade bodies [2] and different types of filaments formed by tubulin, vimentin, actin and myosin [3] . Morphological evidence of endothelial alterations in diabetic retinopathy includes both acellular and hypercellular capillaries and microaneurysms [4] . The acellular vessels are not perfused by blood, but it has not been established whether endothelium is necessary to keep the capillaries patent or whether local ischaemia, secondary to capillary occlusion, leads to cell death. In neuropathy, endothelial cell proliferation may obliterate the lumen of sural nerve capillaries [5] . Acellular capillaries have been described in feet muscles of patients with microangiopathy [6] but it was not specified whether they were perfused or not. Intimal proliferation has also been described in medium-sized coronary arteries of diabetic patients [7] .
Transmission electron microscopy did not show any specific sign of cell damage in retinal [8, 9] , muscle [10] , or skin [11] capillaries, although images of doubtful interpretation, such as thinning of glomerular endothelium [12] and a decreased number [13, 14] of enlarged [15] vesicles in the endothelial cells of muscle capillaries and retinal microaneurysms have been reported. No changes were observed in intracellular organelles in the endothelial cells of the retina or the glomeruli [15] . Similarly to observations with tubulin in peripheral nerves [161, non-enzymatic glycosylation might alter some properties of structural proteins, but no specific studies have been carried out on cytoplasmic filaments in diabetes.
Turnover
One study in scanning electron microscopy reported an increased number of argyrophilic elements in the endothelium of poorly-controlled alloxan-diabetic rab-bits, compared to well-controlled and healthy animals [17] . This finding was interpreted as evidence for accelerated endothelial cell turnover. On the other hand, a number of investigators have shown that, in vitro, DNA synthesis is reduced and replication delayed in endothelial cells subjected to supraphysiological concentrations of glucose in the culture medium [18] [19] [20] . The above data can be reconciled if one bears in mind that endothelial turnover is a rather slow process in the normal adult vessel wall, where mytotic figures are rarely if ever found. Thymidine labelling indexes are very low in retinal capillaries and in the aorta [21] . Secondly, the repair of de-endothelialised areas appears to involve two mechanisms: migration of nearby elements to fill the gaps, followed by replication to re-establish the original cell density [22] . Experimental evidence suggests that the repair of lesions of the monolayer is not hampered in vivo by diabetes [6] nor in vitro by high glucose concentrations [20] . Thus, should endothelial cell death increase to some extent in diabetes, exposure of subendothelium underlying the shed elements could still be prevented by spreading of cytoplasm from neighbouring cells, while sufficient replications for local necessities can reasonably be expected to take place in spite of hyperglycaemia. However, it seems unlikely that cells die more rapidly on the wall of patent vessels in diabetes, as this would presumably be preceded by profound morphological alterations which the extensive studies carried out by transmission electron microscopy have failed to show. In his exhaustive investigation of diabetic retinopathy, Ashton [9] could report only one image of a disrupted endothelial cell, with red cells and platelets adhering to the basement membrane. The numerous areas of de-endothelialisation reported by Dolgov [17] in alloxan diabetic rabbits could have been artifactual, as they were not accompanied by platelet adhesion.
Metabolism
The intracellular metabolic pathways of endothelium have not been studied extensively and the few data available have been collected in heterogeneous models, utilising cells from both micro-and macrovessels of different species.
Glucose appears to be metabolised mainly via anaerobic glycolysis, in isolated cells from both large [23] and small vessels [24] , a feature that might reflect the ability of endothelial cells to tolerate relatively prolonged periods of hypoxia. In vitro, the oxygen consumption decreases when the glucose concentration in the culture medium increases, a phenomenon shared by other tissues, and known as the Crabtree effect [23] .
Studies in cultured retinal capillary endothelium provided evidence that these cells have a facilitative diffusion-type transport system for hexoses, and that they always contain free intracellular glucose [25] . . This hormone has also been reported to increase the uptake of aminoisobutyric acid in bovine aortic endothelial cells [41] and to increase the number of intracytoplasmic vesicles in striated muscle capillaries [14] . Endothelial uptake might also be involved in the clearance of insulin [31] .
The main bulk of the hormone, however, is transferred unaltered from the luminal to the abluminal face of endothelium. This has been elegantly demonstrated in vitro [42] by growing a monolayer of calf aorta endothelium on a membrane permeable to insulin, which separated two chambers containing culture medium. When labelled insulin was added to the "lumi-nal" chamber, transport to the other chamber occurred with a specific, receptor-mediated and saturable mechanism. Internalisation and subsequent release of receptor-bound insulin have also been reported in bovine aortic [38] and brain capillaries [43] .
The mechanisms underlying insulin "transcytosis" after binding to the receptors are at present poorly understood. It appears, however, that endothelial cells of both large and small vessels actively transfer insulin from the blood to the tissues and this, in turn, leads to some further considerations.
Firstly, insulin is not as readily available to muscle and adipose tissue as has been thought, since a delaying continuous endothelial monolayer must be crossed before target tissues are reached [39] . In this context, it would be tempting to speculate that the reported increase of insulin resistance in patients with microangiopathy [44] may reflect impaired transendothelial transport of the hormone, i.e. yet another manifestation of widespread endothelial dysfunction associated with the chronic complications of diabetes.
Secondly, the finding of receptors in the capillaries of tissues that, like the brain and retina, are traditionally considered insulin independent poses further problems. Although insulin does not cross the blood-brain barrier [45] , its binding to cerebral microvessels might still result in metabolic signals for the underlying brain cells [34] . Insulin is also likely to act as a growth factor for the developing central nervous system and its brain uptake, binding to cerebral microvessels and cerebralspinal fluid brain levels were found to be 8 times as high in newborn rats as in adult animals 
Capillary permeability
Capillary permeability has progressively decreased during the evolution of species to permit the development of a complex vascular system and, along with it, of larger and more sophisticated organisms [47] . In fact, the survival of complex organisms is based upon an even distribution of small and large molecules throughout the body, which is obtained in higher vertebrates by increasing the hydrostatic pressure within their vascular system. This, in turn, would lead to massive protein sieving and trapping in the interstitial spaces, which is prevented by the development of a closed and only slightly permeable vascular network and of a lymphatic system to drain large molecules from the interstitium into the venous end of the circulation. However, a "closed" vascular system is never completely sealed, nor would this be desirable. Large protein and even blood cells must be allowed to leave the vessel lumen or, as in the case of hormones, to enter it. Endothelium is the structure controlling these exchanges and has undergone a series of modifications to match local functional requirements in different organs.
In man, at least four histologic types of capillaries are found: sinusoids in the liver, spleen and bone marrow; fenestrated capillaries in the kidney, endocrine glands and gastro-intestinal mucosa; continuous capillaries in striated, cardiac and smooth muscles and, finally, the specialised continuous capillaries of brain and retinal microvessels [48, 49] . In the latter, endothelial cells are joined by continuous zonulae occludentes occasionally reinforced by desmosomes [50] , forming the anatomical correlates of the blood-brain barrier and blood-retinal barrier.
Hyperpermeability of the capillary wall to molecules of different size, ranging from small ions [10, 51] [57] has been reported in patients with microangiopathy. A series of adjustments appears to take place in the diabetic organism in order to avoid protein accumulation in the interstitium and, consequently, an increase of the colloid osmotic pressure. Indeed, a decrease of the latter has been reported, possibly due to overcompensatory capillary filtration of fluid resulting in lymphatic wash-out of interstitial proteins and increased transcapillary colloid osmotic gradient [58] . It is conceivable that this mechanism, while preventing chronic oedema in diabetes, might also account for the above mentioned increased passage of ions and small solutes across the capillary wall.
A number of mechanisms have been suggested to explain the increased transcapillary escape rate of albumin (TERAIb) in microangiopathy. In vitro, glycosylated albumin is avidly taken up by endocytosis in isolated rat capillaries, whereas non-glycosylated albumin is not [60] . Furthermore, in the presence of concentrations of the former mimicking those found in poorlycontrolled patients, the latter is ingested, as well. The same authors have also reported that glycosylation of endothelial cell membrane components is able to increase the uptake of glycosylated albumin, albeit not the native protein, into micropinocytotic vesicles. Another set of experiments showed that the intravenous administration of insulin to diabetic patients, in doses that do not produce hypoglycaemia, is accompanied by a decrease of the intravascular pool of albumin and of plasma volume [61] . When injected into non-treated diabetic rats, insulin was found to acutely normalise the reduced number of intracytoplasmic vesicles in striated muscle capillary endothelium, a finding interpreted as evidence for the re-establishment of transendothelial transport mediated by the hormone [14] . Finally, hypoglycaemia was reported to increase the TERAJb in normal subjects [62] and might occasionally contribute to increased albumin escape from the patients' plasma. However, were these the sole mechanisms at work, one would expect the TERAlb to correlate with metabolic control and/or the degree of hyperinsulinaemia necessary to achieve it. This was not the case in the report of Feldt-Rasmussen et al. [59] , showing that the TERAIb was increased in patients with microangiopathy and microalbuminuria, but not in those with normal urinary albumin excretion, and no or minimal retinopathy. The groups had similar age, sex, duration of disease, daily insulin dose, glycated haemoglobin levels and blood pressure.
Thus, abnormal leakage appears to be a manifestation of microangiopathy rather than a mechanism primitively involved in its pathogenesis. Obviously, it is difficult to organise prospective studies to prove such an assumption. Further "cross-sectional" support for this conclusion could be drawn from evidence of increased permeability of the blood-brain barrier to dopamine in patients with microalbuminuria [52] and of the blood-retinal barrier to fluorescein in patients with background retinopathy as compared to patients with clinically unaffected retinas [55] . However, previous data in the literature had reported breakdown of the blood-retinal barrier in the absence of clinically evident refinopathy [53, 54] and the whole issue is complicated by the finding that, of the two components of the blood-retinal barrier, retinal pigment epithelium rather than retinal capillary endothelium may be responsible for fluorescein leakage in early diabetic retinopathy [63] . In any case, capillary hyperpermeability becomes a main feature of later stages of retinopathy, as gross leakage of the dye from most microaneurysms, capillaries and new vessels is characteristically observed on fluorescein angiograms [64] .
Increased protein passage across endothelium and deposition on the basement membrane may contribute to the ubiquitous thickening of the latter, which is generally considered the hallmark of diabetic microangiopathy. Albumin and other plasma proteins have been demonstrated in the basement membrane of glomerular [65] and dermal capillaries [66] from diabetic patients, not normal control subjects. In turn, the altered basement membrane may become more permeable to the molecules that reach it, as suggested by the reports of sodium fluorescein passing in increased amounts, and more rapidly, the pericapillary collagen sheath of nail-fold capillaries in diabetes [56] . The diffusion capacity for small ions is also increased in striated muscle, but does not correlate with the basement membrane thickness in Type 1 (insulin-dependent) diabetes [10] .
An indication that imbalanced sorbitol/inositol metabolism may contribute to capillary hyperpermeability can be inferred from the observation that aldose reductase inhibition is able to reduce albumin permeation from new vessels of granulation tissue in streptozotocin diabetic rats [67] . However, in that experiment, newly formed capillaries feeding inflammatory tissue induced by subcutaneous polyester fabric were studied; more representative models of the microcirculation in diabetes would be warranted to substantiate this observation in view of its potential practical implications.
Haemostasis
Recent data have shown that endothelium is actively involved in the synthesis of factors that prevent or limit the progression of blood coagulation as well as others that lead to the activation of platelets and of the plasma clotting system. In other words, the long-recognised non-thrombogenic property of endothelium results from a balance between pro-and anti-coagulant activities, the former prevailing in physiologic conditions.
Circulating platelets do not interact with endothelium but promptly adhere to areas of subendothelium when this is exposed to the blood flow [68] . Following adhesion, platelets may aggregate if further elements are recruited and activated, leading to the formation of a white thrombus [69] . Platelet adhesion to subendothelium requires the presence of von Willebrand factor (vWF) [70] , a glycoprotein synthesized by endothelial cells [71] of small and large blood vessels [72] , stored in rod-shaped organelles known as Weibel-Palade bodies [73] and deposited by these cells on to the basement membrane [74] .
Platelet aggregation can be induced, with separate mechanisms, by at least three mediators: thromboxane A2 [75] , ADP [76] and Platelet Activating Factor (PAF) [77] . In the late 1970s, great emphasis [78] had been placed upon the balance between the platelet-derived thromboxane A2 and the endothelial synthesized prostacyclin [79] , the most potent inhibitor of aggregation and, to an extent, adhesion, known so far [80] . However, further observations have shown that platelet/endothelial interactions are far more complex. Endothelial cells also synthesize and release thromboxane A2 [81] and PAF [82, 83] , thus potentially contributing to activate platelets in certain conditions, whereas the presence of membrane ADPase might play a role in preventing aggregation [84] .
A similar co-existence of activating and inhibiting factors has also been observed in the case of the plasma clotting system. On the one hand, heparin-like molecules tightly bound to the endothelial surface [85] act as co-factors for antithrombin III [86] , one of the major physiological anti-coagulant substances, which is itself synthesized by endothelial cells [87] . Another endothelial molecule, thrombomodulin, is involved in the activation of the protein C anticoagulant pathway [88] . On the other hand, thrombin-exposed endothelium synthesizes thromboplastin [89] and exhibits clot retracting activity [90] , while endotoxin-treated endothelial cells have been shown to generate tissue factor [91] , initiating a pro-coagulant pathway, and to recruit platelets leading to the formation of a fibrin clot [92] . Tissue factor-like pro-coagulant activity is also induced by interleukin I [93] .
With regard to the fibrinolytic system, once again endothelial cells have been shown to produce plasminogen activators, including urokinase [94, 95] as well as inhibitors of plasminogen activation [94, 96] . Possibly, activated protein C enhances the activity of the former and reduces that of the latter [97] .
Thus, it appears that the role of the vessel wall in the modulation of haemostasis is complex and little understood. In this light, reports of altered production of clotting-related endothelial molecules in diabetic microangiopathy should be considered as merely descriptive, and efforts to fit such data into pathogenetic hypotheses can only be regarded as speculative. Investigations in diabetic subjects have concerned themselves mainly with vWF, prostacyclin and fibrinolysis.
vWF is increased in the plasma of patients with diabetic microangiopathy [98, 99] and its elevation is associated with retinal capillary hyperpermeability to fluorescein [55] . vWF levels correlate with the age of the patients and the duration of diabetes [100] , i.e. the major risk factors for the development of microvascular complications [101] , but are not influenced by either acute changes of blood sugar or insulin levels [100, 102] or the degree of metabolic control, as assessed by Schlichtkrull's M index [100] and HbAlc [99] . vWF plasma levels may rise in response to stress situations, like hypoglycaemia [103] , hyperglycaemic coma [104] and strenuous exercise [105] . In contrast to earlier reports [106] , they are not influenced by growth hormone levels [100, 107] .
Although vWF is found also in platelets [108] and megakaryocytes [109] , its main storage site is endothelium; the question arose whether the latter synthesizes and releases more glycoprotein or becomes unable to keep it intracellularly and lets it leak into the circulation when subjected to conditions of chronic stress in microangiopathy. Studies in vivo, in which vWF was measured after inducing its release from vascular endothelium into the plasma by venous stasis [110, 111] or 1-deamino-8-D-arginine vasopressin [112] , appear to support the first hypothesis. It is not known whether the clearance of vWF is also affected by diabetic microangiopathy, nor what causes endothelial cells to produce more vWF. A study in vitro had reported increased intracellular content of vWF in cultured endothelium subjected to glucose concentrations mimicking those found in poorly-controlled patients [113] .
This glycoprotein appears to be structurally normal in diabetes [111] ; and glycosylation, if it occurs, may not alter its function [100, 102] . Finally, its increased levels do not alter platelet function, as assessed in vitro by glass bead retention [114] or ADP-induced aggregation [114, 115] .
While it is accepted that diabetic platelets have an increased ability to synthesize thromboxane A2 [116] , data on prostacyclin production are contradictory, as the latter has been reported as reduced [117] [118] [119] , normal [120, 121] and even increased [122, 123] . The perplexities raised by such results may have to remain unanswered for some time to come, as there are still technical problems with the extraction of the stable end-products of prostacyclin from plasma. Work in vitro may partially overcome this problem because culture media containing minor amounts of added serum are processed and indicate reduced prostacyclin production by endothelial cells grown in the presence of diabetic serum [124, 125] though not of high glucose concentrations [126] .
Antithrombin III activity is decreased in diabetes, due to non-enzymatic glycosylation of its active site, not as a consequence of decreased circulating levels of the molecule [127, 128] .
Plasma fibrinolytic activity is reduced in patients with retinopathy both basally and after release of plasminogen activators from endothelium into the blood, as obtained by forearm venous stasis [129] . However, no studies have been carried out in vivo or in vitro to ascertain if this is due to reduced synthesis of plasminogen activators, increased production of their inhibitors or a combination of both. A further contribution to the impaired fibrinolytic activity of plasma may derive from the increased resistance of non-enzymatica!ly glycosylated fibrin to degradation by plasmin [130] .
Angiotensin-converting enzyme
Angiotensin-converting enzyme (ACE) is another circulating glycoprotein synthesized by vascular endothelium [131] which cleaves angiotensin I to angiotensin II and inactivates bradykinin [132] . Two studies have reported supra-normal levels of serum ACE in some diabetic patients. In the first one [133] , 18% of 232 control subjects had elevated ACE on a cross-sectional basis and, upon repeating the test several times over 1 year, another 6% showed sporadically increased values. Since the prevalence of retinopathy was higher in the group with high ACE, the authors concluded that this parameter may indicate widespread endothelial damage in microangiopathy. In the second paper [134] , 9% of 56 diabetic patients were found with increased serum ACE but vascular complications were not assessed. ACE decreased to normal in 6 patients when ketoacidosis developed as a result of insulin withdrawal. In our laboratory [135] , normal levels of serum ACE were measured in 12 patients with retinopathy and increased plasma vWF. Forearm venous stasis was able to release ACE from endothelium to a similar extent in the diabetic patients and in healthy control subjects.
Taken together, the above results suggest that serum ACE is increased in a minor share of patients with diabetic microangiopathy and may be a poorer indicator of endothelial damage than vWF. Indeed, ACE is more characteristically increased in chronic granulomatous diseases, such as sarcoidosis, Gaucher's disease and leprosy [133] .
Angiogenesis
This term indicates the process by which endothelial cells migrate from pre-existing capillaries into avascular sections of various tissues and proliferate to form new vessels. This is a physiological event in embryonic development and in the endometrium, during the menstrual cycle. Pathological new vessels develop in wound healing, inflammatory tissue, tumour growth and diabetic retinopathy.
In the latter condition, neovascularisation occurs in association with large areas of capillary non-perfusion in the peripheral retina. In addition, hypercellular microaneurysms have been interpreted by some authors as abortive attempts at new vessel formation, because they are more often observed at the borders of nonperfused areas [101] . These observations have led to the suggestion that factor(s) released from the ischaemic retina may act as effector(s) of new vessel proliferation but no such factors have been identified with certainty. Elevated concentrations of the angiogenetic fibroblast growth factor were measured in the ocular fluid of diabetic patients undergoing vitrectomy [136] . However, a more complicated interplay may take place among pro-and anti-angiogenetic molecules in the human eye, as inhibitors of endothelial cell proliferation have been reported in the vitreous of non-diabetic as well as diabetic individuals [137] . Furthermore, it may not be necessary to postulate the synthesis of a specific substance to induce endothelial proliferation in diabetic retinopathy. A number of physiologically occurring molecules or their breakdown products are able to induce endothelial cell migration and/or neovascularisation in vivo, including heparin [138] , PGE1 [139] , PGE2 [140] , hyaluronic acid degradation products [141] , and angiotensin II [142] . Angiogenesis can also be induced in vivo by human follicular fluid [143] and extracts from myocardial infarcts [144] and is facilitated by copper ions, fibronectin and some gangliosides [139] .
Conclusions
Endothelial cells are directly exposed to altered concentrations of circulating metabolites in diabetes and are likely to be involved early, if not primarily, in the natural history of the chronic complications of the disease. Thus, better understanding of the mechanisms underlying endothelial dysfunction and of their possible pathogenetic relevance might help to establish a rationale on which to base prospective trials for the prevention or treatment of microangiopathy.
A word of caution should be made in warning that most data available today are derived from experiments in vitro or carried out under highly perturbed conditions in vivo and that virtually none of the methods employed has so far been standardised among different laboratories. Hence, it should come as no surprise if some results are in conflict with each other or will be refuted in the near future. Work on endothelium has only just begun and much still has to be done in this fascinating field of investigation. 
